

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		ATTORNEY'S DOCKET NUMBER <b>700953-53666</b>
INTERNATIONAL APPLICATION NO. <b>PCT/US2004/037810</b>	INTERNATIONAL FILING DATE <b>12 November 2004 (12.11.2004)</b>	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>107579007</b> To be assigned
PRIORITY DATE CLAIMED <b>12 November 2003 (12.11.2003)</b>		
TITLE OF INVENTION <b>SYSTEM FOR TREATING AND PREVENTING BREAST CANCER</b>		
APPLICANT(S) FOR DO/EO/US <b>Therion Biologics Corporation, et al.</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ul> </p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ul> </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
<p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p>		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>107579007</b> To be assigned	INTERNATIONAL APPLICATION NO. <b>PCT/US2004/037810</b>	ATTORNEY'S DOCKET NUMBER <b>700953-53666</b>
---	---	---

## 20. Other items or information:

Exp. Mail Cert. EV653005037US; COPY-Cert. of Limited Recognition; ORIGINAL-Statement Accompanying Seq. Listing; ORIGINAL-Seq. Listing; ORIGINAL-CRF; Statement Accompanying Substitute Seq. Listing; PAPER COPY-Substitute Seq. Listing; Substitute-CRF; COPY-Assignment from Parent; COPY-Int'l Search Report; COPY-References B1 and C1-C6 and Return Receipt Postcard.

The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21. <input checked="" type="checkbox"/> Basic national fee (37 CFR 1.492(a))..... \$300				\$ 300.00	
22. <input checked="" type="checkbox"/> Examination fee (37 CFR 1.492(c))  If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0 All other situations..... \$200				\$ 200.00	
23. <input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority..... \$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB..... \$400 All other situations..... \$500				\$ 100.00	
<b>TOTAL OF 21, 22 and 23 =</b>				600.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
99 - 100 =	-1 /50 =		x \$250	\$ 0.00	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	43 - 20 =	23	x \$ 50	\$ 1,150.00	
Independent claims	8 - 3 =	5	x \$200	\$ 1,000.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360	\$ 0.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 2,880.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.				0.00	
<b>SUBTOTAL =</b>				\$ 2,880.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$	0.00
<b>TOTAL NATIONAL FEE =</b>				\$	2,880.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	0.00
<b>TOTAL FEES ENCLOSED =</b>				\$	2,880.00
				Amount to be refunded:	\$
				Amount to be charged	\$

10/579007

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


1AP20 Rec'd PCT/PTO 11 MAY 2008

- a.  A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.
- b.  Please charge my Deposit Account No. 50-0850 in the amount of \$ 2,880.00 to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0850. A duplicate copy of this sheet is enclosed.
- d.  Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.**

SEND ALL CORRESPONDENCE TO:

Ronald I. Eisenstein  
Nixon Peabody LLP  
100 Summer Street  
Boston, MA 02110  
US



SIGNATURE

Ronald I. Eisenstein/Leena H. Karttunen

NAME

30,628

REGISTRATION NUMBER

10/579007

AP20 Rec'd PCT/PTO 11 MAY 2006

Practitioner's Docket No. 700953-53666

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date
PCT/US2004/037810	12 November 2004 (12.11.2004)	12 November 2003 (12.11.2003)

TITLE OF INVENTION: SYSTEM FOR TREATING AND PREVENTING BREAST CANCER

APPLICANT FOR DO/US: THERION BIOLOGICS CORPORATION, et al.


**VERIFIED CERTIFICATION OF EXPRESS MAILING DATE  
(INTERNATIONAL APPLICATION (37 C.F.R. section 1.10(c)))**

I declare that, on May 11, 2006 I deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number EV653005037US, addressed to the "MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450," and having an express mail certification that I executed, the following papers:

1. Express Mail Certificate EV653005037US (1 pg.);
2. COPY-Certificate of Limited Recognition (1 pg.);
3. Transmittal Letter Under 35 U.S.C. 371 – page 3 in duplicate (4 pp.);
4. Application Data Sheet (3 pp.);
5. Preliminary Amendment (9 pp.) and Appendices (6 pp.);
6. ORIGINAL - Statement Accompanying Sequence Listing (1 pg.);
7. ORIGINAL – Sequence Listing (6 pp.);
8. ORIGINAL – Computer-Readable Form of Sequence Listing (1 diskette);
9. Statement Accompanying Substitute Sequence Listing (1 pg.);
10. PAPER COPY – Substitute Sequence Listing (6 pp.);
11. SUBSTITUTE Computer-Readable Form of Sequence Listing (1 diskette);
12. COPY – Assignment from Parent (7 pp.);
13. Information Disclosure Statement, including Form 08a and b (4 pp.);
14. International Search Report - Form PCT/ISA/210 (5 pp.);
15. COPY – References B1 and C1-C6 cited in International Search Report; and
16. Return Receipt Postcard.

A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.



Date: May 11, 2006

Linda M. Ginsberg  
(type or print name of person certifying)

10/579007

AP20 Rec'd PCT/PTO 11 MAY 2006


BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATES PATENT AND TRADEMARK OFFICE

**LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)**

Leena H. Karttunen is hereby given limited recognition under 37 CFR §11.9(b) as an employee of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is the client of Nixon Peabody LLP and an attorney or agent of record in the applications is a registered practitioner who is a member of Nixon Peabody LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with Nixon Peabody LLP ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. L0207  
Expires: February 11, 2007

  
\_\_\_\_\_  
Harry I. Moatz  
Director of Enrollment and Discipline